MARKET

PRTC

PRTC

Puretech Health
NASDAQ
19.00
+1.09
+6.09%
Closed 15:11 05/22 EDT
OPEN
19.00
PREV CLOSE
17.91
HIGH
19.00
LOW
19.00
VOLUME
1.49K
TURNOVER
0
52 WEEK HIGH
32.98
52 WEEK LOW
13.30
MARKET CAP
456.36M
P/E (TTM)
9.65
1D
5D
1M
3M
1Y
5Y
1D
Positive Outlook on PureTech Health Driven by Promising LYT-100 Clinical Trial Results and Strategic Developments
TipRanks · 7h ago
PureTech to Present at the Jefferies Global Healthcare Conference
Barchart · 1d ago
PureTech Health presents deupirfenidone data at ATS conference
TipRanks · 2d ago
PureTech Presents Phase 2b Data For Deupirfenidone At ATS 2025, Showing Statistically Significant Slowing Of IPF Progression With Durable Effect Over 52 Weeks, Favorable Safety Profile, And Plans For FDA Meeting And Phase 3 Trial Launch By End Of 2025
Benzinga · 2d ago
PureTech’s Deupirfenidone (LYT-100) Demonstrates Strong and Durable Efficacy as a Monotherapy with Favorable Tolerability in Phase 2b ELEVATE IPF Trial
Barchart · 2d ago
Weekly Report: what happened at PRTC last week (0512-0516)?
Weekly Report · 4d ago
Weekly Report: what happened at PRTC last week (0505-0509)?
Weekly Report · 05/12 11:09
PureTech Health publishes new research in BMC Pulmonary Medicine
TipRanks · 05/09 11:30
More
About PRTC
PureTech Health plc is a clinical-stage company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company is engaged in the development of around 29 therapeutics and therapeutic candidates, including three that have been approved by the United States Food and Drug Administration. A number of these programs are advanced by the Company or its Founded Entities in various indications and stages of clinical development. Its primary programs include LYT-100 and LYT-200. Deupirfenidone (LYT-100) is being developed as a potential new standard of care (SOC) for the treatment of idiopathic pulmonary fibrosis (IPF). LYT-200 is an anti-galectin-9 monoclonal antibody (mAb) being developed for the treatment of hematological malignancies, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS), as well as solid tumors, including head and neck cancers, with a focus on metastatic disease.

Webull offers PureTech Health PLC (ADR) stock information, including NASDAQ: PRTC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PRTC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PRTC stock methods without spending real money on the virtual paper trading platform.